Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America (“The RTP GMP Manufacturing Facility”) has started GMP production of autologous CAR T-cell products and successfully released the first GMP batch for the clinical trials.

The RTP GMP Manufacturing Facility, with a total gross floor area of approximately 3,300 sq.m, will provide CARsgen additional manufacturing capacity of autologous CAR T-cell products for 700 patients annually to support clinical studies and early commercial launch in North America and Europe. “I am very pleased to announce that the RTP Manufacturing Facility has achieved the company’s target of releasing the clinical batches for the U.S. patient use in Q3, 2022,” said Mr. Richard Daly, President of CARsgen Therapeutics Corporation. “CARsgen is rapidly expanding the in-house capacity of manufacturing and quality testing in the United States. The company will accelerate the ongoing clinical studies by providing more promising CAR T-cell products to the global patients.”

“The successful release of the first U.S. patient product at the RTP GMP Manufacturing Facility is a remarkable milestone for CARsgen and our trusted partners,” added by Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited. “By taking the advantage of the vertically integrated production at CARsgen, our world-class CMC team could complete the global technology transfer from our China manufacturing facility and then advance to the clinical manufacturing effectively. The commencement of clinical production at the RTP GMP Manufacturing Facility will greatly reduce current risks of global supply chain shortage and strengthen the value chain of CARsgen.”

Apart from several ongoing clinical studies in China, the company has two active INDs, including a Phase 2 pivotal study of CT053 for relapsed/refractory multiple myeloma and a Phase 1b study of CT041 for advanced gastric and pancreatic cancers, both cleared by the U.S. FDA and the Health Canada. In fact, CARsgen is the only CAR T company to have received RMAT and PRIME designations for both heme (CT053) and solid (CT041) tumor therapies.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine